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Abstract 
With the aim to develop novel HIV-1 integrase inhibitors, we obtained a set of condensed ring 
systems based on the furo[2,3-h]cinnolin-3(2H)-one and pyridazino[3,4-f]cinnolin-3-ol scaffolds 
bearing a potential chelating pharmacophore, which can be involved in the inhibition mechanism 
of the enzyme. Herein, we report the design, synthesis, structural investigation and preliminary 
biological results of these heteroaromatic systems.  
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Introduction 
 
HIV-1 integrase (IN), the viral enzyme that catalyzes the integration of proviral cDNA into the 
host cell genome, has emerged as an attractive target for novel anti-AIDS agents.1-3 The first IN 
inhibitor (e.g. raltegravir, Isentress) was recently approved by the US FDA,4 and other IN 
inhibitors are in clinical trials or under clinical investigation.5,6 These compounds belong to a 
class of compounds bearing a β-diketo acid (DKA) pharmacophoric motif, which are the most 
promising lead in anti-IN drug discovery.7,8 Starting from the simple benzoylpyruvic acid 1 
(BPA, Figure 1a), other members of the DKA family, exemplified by L-731,988 2 have been 
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reported and intensively studied.8,9 Moreover, several DKA bioisosteric analogues have been 
discovered.9 
DKAs are comprised of three structural components (Figure 1b): a β-diketo moiety (a), an 
aromatic or heteroaromatic portion (b), and a carboxylic functionality, which can be replaced 
with a variety of bioisosteric functions (c).9 Although the mechanism by which they bind IN has 
not been well understood, it is believed that the β-diketo acid pharmacophoric motif could be 
involved in a functional sequestration of one or both divalent metal ions in the enzyme catalytic 
site, to form a tertiary ligand-M2+-IN complex (Figure 1c).1 DKAs represented a good starting 
point for medicinal chemistry discovery and optimization programs, and it has been well suited 
to explore this chemical space by considering structurally related prototypes. In this context, it is 
of great interest to develop a new generation of novel and selective IN inhibitors as well as to 
investigate their mechanism of action. 
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Figure 1. (a) Representative DKAs inhibitors. (b) Chemotype of DKA β-diketo-based inhibitors. 
(c) The two-metals binding model previously proposed for selective strand-transfer chelating 
inhibitors. The atoms ‘X’ and ‘Y’ represent possible hetero-atoms that serve a lone-pair and the 
semicircles indicate heteroaromatic rings, optionally including the ‘C═X’ or ‘C═Y’ bond. 
Metals are depicted as grey spheres. 
 
In the course of our drug discovery program focused on developing original IN inhibitors,10-
15 a series of polycyclic templates carrying a novel potential chelating pharmacophore has been 
designed and synthesized. Our attention was addressed to the furo[2,3-h]cinnolin-3(2H)-one 
scaffold I (Figure 2), as analogue of the previoulsy reported 6-aryl-5-methyl-4,5-dihydro-3-
(2H)pyridazinones, 4,4a-dihydro-5H-indeno[1,2-c]pyridazinones II, III,16-19 and more strictly to 
5,6-dihydrobenzo[h]-, 5,6-dihydrothieno[2,3(3,2)-h]cinnolin-3(2H)-ones IV, V.20-22     
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These condensed ring systems demonstrated a versatile platform to incorporate a pyridazinone 
ring, which has shown several pharmaceutical properties.23 In this context, the N-NH-CO-C-R 
(R = OH, NH2) motif could be considered as a potential chelating fragment, eventually suitable 
of bioisosteric replacement of the β-diketo enol pharmacophore. Moreover, furan oxygen of the 
heteroaromatic backbone, can be involved in potential hydrogen bonding with amino acid 
residues on the active site. 
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Figure 2. Design of furo[2,3-h]cinnolin-3(2H)-one scaffold I, and previously reported 
pyridazinones II, III and cinnolinones IV, V. 
 
On this basis, the preparation of a first set of furo[2,3-h]cinnolin-3(2H)-one 3-5 has been 
performed (Figure 3). 
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Figure 3. Potential chelating fragments of the designed furo[2,3-h]cinnolin-3(2H)-ones. 
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Results and Discussion 
 
The synthetic routes for the preparation of cinnolinones 3-5 are depicted in Scheme 1. 5,6-
dihydrofuro[2,3-h]cinnolin-3(2H)-one 3 was synthesized (62% yield) by refluxing the 
hydroxy(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-5-yl)acetic acid 6 in an excess of hydrazine 
hydrate for 30 minutes. The intermediate α-hydroxy acid 6 was obtained by reacting the 6,7- 
dihydro-1-benzofuran-4(5H)-one 7 with equimolar amount of glyoxylic acid in an aqueous 
solution of sodium hydroxide at room temperature. Addition of chloroacetaldehyde to 1,3-
cyclohexanedione 8, following a previously reported procedure,24 afforded the ketone 7 in high 
yield (Scheme 1). 4-hydroxy-4,4a,5,6-tetrahydrofuro[2,3-h]cinnolin-3(2H)-one 4 was obtained 
(32% yield) by condensation of the key intermediate 6 with an equimolar amount of hydrazine 
hydrate in refluxing ethanol for 1 hour. It is noteworthy that if 4 is treated with hydrazine hydrate 
in acidic condition and refluxed for several hours, dehydration of 4 to 3 is expected, according to 
the previously reported method.22 
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Scheme 1. Reagents and conditions: i: chloroacetaldehyde, aq. NaHCO3, rt, 15 hours; ii: 
glyoxylic acid monohydrate, aq. NaOH, 0 °C then rt; iii: hydrazine monohydrate, reflux, 30 min; 
iv: hydrazine monohydrate, ethanol, reflux, 1 hour; v: LiHMDS -78 °C , ethyl bromoacetate, -70 
°C for 1 hour, then rt for 18 hours; vi: 10% aq. NaOH, MeOH, reflux, 2 hours; vii: hydrazine 
monohydrate, ethanol, reflux, 3 hours. 
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4,4a,5,6-Tetrahydrofuro[2,3-h]cinnolin-3(2H)-one 5 was obtained (38% yield) by reaction 
with hydrazine hydrate in refluxing ethanol for 3 hours of the (4-Oxo-4,5,6,7-tetrahydro-1-
benzofuran-5-yl)acetic acid 9, which was obtained in good yield by alkaline hydrolysis of the 
corresponding ester 10. The latter was prepared by alkylation of the ketone 7 with ethyl 
bromoacetate in THF solution of LiHMDS at -78 °C (Scheme 1).  
Compounds 3-5 were fully characterized by means of NMR spectroscopy, mass spectrometry 
and elemental analysis. In particular, these systems presented a common pattern of signals, 
constituted by broad singlets for the exchangeable NH protons in the range of 10-13 ppm, and 
two doublets at 7.69-7.63 and 6.75-6.61, for H8 and H9, respectively, of the furan ring. In 
addition to the other aromatic H4 proton, compound 3 revealed a multiplet in the range of 3.02-
2.93 ppm, attributable to H5 and H6, whereas a more complicated signal pattern ranging from 
3.94 to 1.73 ppm was observed for compound 4. The latter also displayed a deuterium oxide 
exchangeable proton of the OH function located in position 4. As for compound 5 H4 proton 
appeared upfield as a multiplet centered at 2.84 ppm. 
Further exploration of this chemistry resulted in the synthesis of cinnolinones 11-14. When 
ketone 6 was refluxed in excess of hydrazine hydrate for 48 hours, furo[2,3-h] cinnolin-3(2H)-
one 11 was isolated in 35% yield (Scheme 2). The structure of 11 has been confirmed by means 
of the above-mentioned analytical methods. As far as 1H-NMR results are concerned, the five 
aromatic protons are detected at 7.75 (singlet, H4), 7.68 (AB system, H6 and H5), 7.62 (doublet, 
H8) and 6.61 (doublet, H9) ppm resonance. 
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Scheme 2. Reagents and conditions: i: hydrazine monohydrate reflux, 48 hours; ii: 72 hours; iii: 
24 hours; iv: 15-30 min. NOE correlations are indicated for 13. 
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According to the above-mentioned behavior,22,25 the 4-amino-furo[2,3-h]cinnolin-3(2H)-one 
12 (40%) was synthesized by refluxing 6 in hydrazine hydrate for about 72 hours. The formation 
of 12 (45%) also occurred starting from 11 under the same conditions and refluxing for 24 hours. 
When the reaction time between 11 and hydrazine hydrate was increased to 72 hours, a new 
heterocycle, namely 4-amino-1,2-dihydropyridazino[3,4-f]cinnolin-3-ol 13, was obtained in 25% 
yield (slightly impure of 11). The formation of this compound, in which the furan ring was 
converted to an additional pyridazine ring, is discussed below (Figure 5). 
Focusing on 13, in addition to the two expected doublets detected at 8.05 and 7.57 ppm for 
H5 and H6, respectively, the 
1H-NMR spectrum exhibited two other doublets at downfield 
centered at 9.34 and 8.47 ppm, attributed to the H9 and H10, respectively. The coupling constant 
values (J = 5.5 Hz) of these signals are in accordance with similar patterns in the cinnoline ring, 
further supporting its formation. Also, exchangeable broad singlets detected at 13.50, 7.64, and 
6.20 were assigned to the enolic OH in position 3, the NH protons in position 1 and 2, and the 
NH2 group in position 4, respectively.  
Then, when cinnolinone 3 was kept in refluxing hydrazine hydrate for 15-30 minutes, it was 
converted into 55% of its tautomer 1,2-dihydrofuro[2,3-h]cinnolin-3(4H)-one 14. In particular, 
the 1H-NMR spectrum of 14 was characterized by a singlet at 3.59 ppm (H4), a singlet at 7.18 
ppm (overlapping H8 and H9), two doublets centered at 7.94 and 7.20 ppm, for H6 and H5, 
respectively, and by an exchangeable broad singlet at 5.33 ppm, corresponding to the two NH in 
positions 1 and 2. Further prolonging of reaction time of 14, can reasonably give 11 according to 
a previously observed behavior for similar reaction22 (data not shown). Further magnetic 
resonance techniques such as DEPT/APT, COSY and NOESY (i.e. compound 13, Scheme 2) 
support the assigned structures for title compounds. A mechanistic hypothesis for the formation 
of the above-mentioned compounds (11 and/or 14) is displayed in Figure 4.  
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Figure 4. Mechanistic hypothesis for the formation of cinnolinones 11 and 14. 
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The reaction process can start through an initial tautomerization of 3 to [3a] and 14, which 
can evolve to give 11 by dehydrogenation in an oxidative step mediated by hydrazine according 
to the different experimental conditions, whose N-N bond is cleaved to give two ammonia 
molecules. 
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Figure 5. Mechanistic hypothesis for the formation of cinnolinones 12 and 13. 
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Amination at the 4-position of the pyridazinone moiety of 11 to give compounds 12 and 13 
was explained according with the mechanism (A, Figure 5) proposed by Singh26 and Cignarella 
et al.25 Briefly, this reaction occurs through an initial 1,4 addition of hydrazine to the 
pyridazinone ring, to form the intermediate 11’, which, by dehydrogenation and final amination 
to the 4,4a-5,6 conjugated system, leads to 12 (and stage one of 13, Figure 5). However, the 
alternative mechanism (B, Figure 5), with the initial formation of the intermediate 11", 
according with previously reported by Shemyakin et al.27 and Cignarella et al.28 can also be 
considered. Although these compounds can directly be obtained from 6, we can reasonably 
hypothesize that this reaction may proceed via compound 11. The complete formation of 13 can 
occur by a second-stage mechanism which involves another hydrazine addition to the furan ring 
of 12 (at position 8 of the furocinnolinone scaffold) to give the intermediate 12a, following by a 
ring-opening to give 12b (Figure 5). The formation of the intermediate 12a can also involve a 
starting furan epoxydation, which is well-documented in the literature,29 and that can facilitate 
the Michael addition of hydrazine. Intramolecular nucleophilic attack to the carbonyl group 
would be carried out by the N1-amino group of the hydrazine coupled to give a six-membered 
ring 12c, which led to 13 by a final prototropic rearrangement with loss of a molecule of water.  
The cinnolin-3(2H)-ones 3-5, 11, 12, the cinnolin-3-ol 13, and the intermediate 6, were tested 
for their ability to inhibit IN catalytic activities in in vitro assays employing purified enzyme 
(Table 1). Inhibitors 1 and 2 were used as reference compounds.15 With the exception of 12 and 
13, all tested cinnolinone-derivatives, as well as the intermediate 6, did not show any anti-IN 
activities. Conversely, the 4-amino-derivatives 12 and 13, shared a certain inhibitory activity, 
thus demonstrating some inhibitory properties of this novel chemical scaffold. With a IC50 of 60 
± 13 μM against strand transfer reaction, 13 proved to be the most active compound of the series.  
 
Table 1. Inhibition of HIV-1 integrase catalytic activities 
Cpds 
3’-Processing 
IC50 (µM) 
Strand Transfer 
IC50 (µM) 
SIa 
1 >333 69 ± 4 >5 
2 15 ± 2 0.54 ± 0.08 28 
3 >100 >100 - 
4 >100 >100 - 
5 >100 >100 - 
6 >100 >100 - 
11 >100 >100 - 
12 >100 96 ± 6 >1 
13 >100 60 ± 13 >1.7 
14 NDb NDb NDb 
aSI: Selectivity Index. Values are from average of two or three independent experiments. bND: 
not determined. 
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Interestingly, when compared with reference compound 1, the derivative 13 demonstrated 
approximately the same inhibitory activities (IC50 values of 60 ± 13 and 69 ± 4 μM for 13 and 1, 
respectively), thus confirming that several features of these systems could be considered for a 
structural development. Furthermore, as expected, 13 proved to be more of 100-fold less active 
of 2, a well studied and validated DKA inhibitor. From a structural point of view, an amino 
functionality in position 4 (both for 12 and 13) and the enol OH in position 3 (only for 13) of the 
pyridazinone ring can be predicted as an additional point of chelation on this pharmacophoric 
fragment, and are important for the anti-IN activity. 
 
 
Conclusions 
 
In this work, a series of novel heterocycles have been designed and synthesized, to be used as 
versatile platform in drug design of IN inhibitors. The inhibition of IN enzyme as well as several 
different viral processes have been targeted via metal chelation. Since the central role of divalent 
metal ions in these transformations, inhibitors of such processes can be designed on 
pharmacophores that bind and/or interact to these divalent metal ions. This work has mainly 
focused in the designing and synthesis of novel chemical scaffold containing a chelating motif 
addressed toward metal-containing enzymatic sites, such as IN as virological target. Based on the 
data presented here, these novel prototypes might affect metal affinity in the context of the active 
site binding. These results prompted us to propose that these types of chromophore are suitable 
for extensive modifications and will be undertaken in future studies. Therefore, further synthetic 
and biological investigation for some related congeners are currently in progress and will be 
reported elsewhere.  
 
 
Experimental Section 
 
General. Anhydrous solvents and all reagents were purchased from Sigma-Aldrich, Merck or 
Carlo Erba. All reactions involving air- or moisture-sensitive compounds were performed under 
a nitrogen atmosphere using oven-dried glassware and syringes to transfer solutions. Melting 
points (mp) were determined using an Electrothermal melting point or a Kofler apparatus. 
Nuclear magnetic resonance (1H-NMR, 13C-NMR, DEPT, COSY, and NOESY) spectra were 
determined in CDCl3, DMSO-d6 or CDCl3/DMSO-d6 (in 3/1 ratio) and were recorded at 200 
MHz and 500 MHz on a Varian XL-200 and a Bruker Avance 500, respectively. Chemical shifts 
(δ scale) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) used as 
an internal standard. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; 
q, quadruplet; m, multiplet; brs, broad singlet; dd, double doublet. The assignment of 
exchangeable protons (OH and NH) was confirmed by the addition of D2O. Electron ionization 
and MALDI-TOF mass spectra (70 eV) were recorded on a Hewlett-Packard 5989 Mass Engine 
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Spectrometer and on a MALDI micro MX (Waters, micromass) equipped with a reflectron 
analyser, respectively. Analytical thin-layer chromatography (TLC) was carried out on Merck 
silica gel F-254 plates. Flash chromatography purifications were performed on Merck Silica gel 
60 (230-400 mesh ASTM) as the stationary phase. Elemental analyses were performed on a 
Perkin-Elmer 2400 spectrometer at Laboratorio di Microanalisi, Dipartimento di Chimica, 
Università di Sassari (Italy), and were within ±0.4% of the theoretical values. 
5,6-Dihydrofuro[2,3-h]cinnolin-3(2H)-one (3). A solution of α-hydroxy acid 6 (0.22 g, 0.0011 
mol) and hydrazine hydrate (5 mL, 0.10 mol) was refluxed for 30 min. After cooling, the product 
was filtered and washed with ethanol to give beige crystals. Yield: 62%; mp 219-220 ºC. 1H-
NMR (200 MHz, DMSO-d6): δ 12.65 (brs, 1H, NH), 7.69 (d, 1H, J = 2.0 Hz, H8), 6.75 (d+s, 2H, 
J = 2.0 Hz, H9 and H4), 3.02-2.93 (m, 4H, H5 and H6). MS (EI): m/z [188, M
+], 159, 132, 131, 
104, 103. Anal. Calc. for C10H8N2O2: C, 63.82; H, 4.28; N, 14.89.  Found: C, 63.70; H, 4.11; N, 
15.15. 
4-Hydroxy-4,4a,5,6-tetrahydrofuro[2,3-h]cinnolin-3(2H)-one (4). A solution of α-hydroxy 
acid 6 (0.105 g, 0.0005 mol) and hydrazine monohydrate (0.025 g, 0.0005 mol) in ethanol (5 
mL) was refluxed for 1 hour. After cooling, the product was filtered, washed with ethanol to give 
the titled compound as yellow-beige crystals. Yield: 32%; mp 273-274 ºC. 1H-NMR (200 MHz, 
DMSO-d6): δ 10.76 (s, 1H, NH), 7.63 (d, 1H, J = 1.8 Hz, H8), 6.61 (d, 1H, J = 1.8 Hz, H9), 5.61 
(brs, 1H, OH), 3.94-3.85 (m, 1H, H4), 2.8-2.65 (m, 4H, H5, H6), 1.73 (m, 1H, H4a). 
13C-NMR 
(DMSO-d6): 169.0, 157.7, 146.5, 143.3, 116.4, 105.8, 67.4, 27.4, 21.7. MS (EI): m/z [206, M
+], 
178, 177, 150, 132, 106. Anal. Calc. for C10H10N2O3: C, 58.25; H, 4.89; N, 13.59. Found: C, 
58.43; H, 4.99; N, 13.77. 
4,4a,5,6-Tetrahydrofuro[2,3-h]cinnolin-3(2H)-one (5). A solution of acid 9 (0.097 g, 0.0005 
mol) and hydrazine hydrate (0.025 g, 0.0005 mol) in ethanol (5 mL) was refluxed for 3 hours. 
After cooling, the product was filtered and washed with ethanol to give a beige solid. Yield: 
38%; mp 224-225. 1H-NMR (200 MHz, DMSO-d6): δ 10.73 (s, 1H, NH), 7.64 (d, 1H, J = 1.8 
Hz, H8), 6.64 (d, 1H, J = 1.8 Hz, H9), 2.82 (m, 2H, H4), 2.52-2.14 (m, 2H, H5), 2.25-2.18 (m, 2H, 
H6), 1.67(m, 1H, H4a).
 13C-NMR (200 MHz, DMSO-d6): 191.2, 166.8, 157.3, 143.2, 116.2, 
105.81, 33.1, 31.7, 28.9, 22.0. MS (EI): m/z [190, M+], 162, 133, 119, 106. Anal. Calc. for 
C10H10N2O2: C, 63.15; H, 5.30; N, 14.73. Found: C, 63.27; H, 5.22; N, 14.88. 
Hydroxy(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-5-yl)acetic acid (6). To a vigorously stirred 
solution of the ketone 7 (0.73 g, 0.0054 mol) and glyoxylic acid monohydrate (0.50 g, 0.0064 
mol) in H2O (10 mL) at 0 
oC, a solution of sodium hydroxide (0.75 g, 0.0188 mol) in H2O (40 
mL) was then added in small portions. After stirring for 40 min. at room temperature, the 
alkaline solution was washed with ethyl acetate (10 mL) and then was acidified at 0 oC with 
concentrated HCl. After stirring at room temperature for 1 hour, the solution was extracted with 
ethyl acetate (6 times), dried over Na2SO4 and concentrated to give yellow heavy oil, which 
solidified to give a white solid. Yield: 81%; mp 135-136 ºC.  1H-NMR (200 MHz, DMSO-d6): δ 
12.58 (brs, 1H, COOH), 7.69 (d, 1H, H8), 6.68 (d, 1H, H9), 5.32 (brs, 1H, OH), 4.72-4.28 (2d, 
1H, Cα-H), 2.96-2.84 (m, 3H, H2, H4), 2.18-2-1.97 (m, 2H, H3). 13C-NMR (200 MHz DMSO-
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d6): 192.4, 175.5, 167.3, 143.8, 120.6, 106.5, 69.6, 68.3, 49.8, 22.3. MS (EI): m/z [210, M
+]. 
Anal. Calc. for C10H10O5: C, 57.14; H, 4.80. Found: C, 57.02; H, 4.98. 
6,7-Dihydro-1-benzofuran-4(5H)-one (7). To an ice-bath cooled solution of 1,3-
cyclohexadione 8 (2 g, 0.0178 mol) and H2O (16 mL), a solution of  NaHCO3 (1.79 g) in H2O 
(16 mL) was added dropwise, followed by a 45% aqueous chloroacetaldehyde solution (3.57 mL, 
0.056 mol), under vigorous stirring. The reaction mixture was stirred at room temperature for 15 
hours (the pH of the solution should be in the range of 6-9). Then ethyl acetate (25 mL) was 
added and the solution was acidified to pH 1 with 1 M H2SO4. After extraction with ethyl acetate 
the organic layers were washed with an aqueous solution of K2CO3, dried over Na2SO4 and 
evaporated under vacuum, to give yellow oil. Yield: 70%. 1H-NMR (200 MHz, CDCl3): δ 7.31 
(d, 1H, H9), 6.69 (d, 1H, H9), 2.91-2.85 (m, 2H, CH2), 2.53-2.47 (t, 2H, CH2), 2.23-2.11 (m, 2H, 
CH2). The 
1H-NMR spectrum was in accordance with that reported in literature.24 13C-NMR (200 
MHz, CDCl3): 194.7, 167.2, 142.5, 120.9, 106.3, 37.5, 23.2, 22.5.  MS (EI): m/z [136, M
+]. 
(4-Oxo-4,5,6,7-tetrahydro-1-benzofuran-5-yl)acetic acid (9). To a solution of ester 10 (2.0 g, 
0.009 mol) in methanol (10 mL), a 10% solution of NaOH in methanol (10.8 mL, 0.027 mol) 
was added, and the mixture was stirred at reflux for 2 hours. After this time, the solvent was 
removed under reduced pressure, the residue was dissolved in water, washed with CH2Cl2, and 
acidified with concentrated HCl. The precipitate formed was filtered and the solid was 
recrystallized from H2O to give the acid 9 as white crystal. Yield 92%.  mp 100°C (Lit. 103-104  
ºC).30 1H-NMR (200 MHz, DMSO-d6): δ 12.12 (s, 1H, OH), 7.66 (d, 1H, H2), 6.64 (d, 1H, H3), 
2.74-2.93 (m, 3H, H5 and 2H7), 2.66 (dd, 1H, HCH-COOH), 2.34 (dd, 1H, HCH-COOH), 2.18- 
2.20 (m, 1H, 1H6), 1.97 (dq, 1H, 1H6). MS (EI): (m/z): [194, M
+].  
Ethyl (4-oxo-4,5,6,7-tetrahydro-1-benzofuran-5-yl)acetate (10). A solution of 7 (1.6 g, 0.012 
mol) in anhydrous THF (15 mL) was added dropwise under a nitrogen atmosphere at -70 oC to a 
1 M solution in THF of lithium bis(trimethylsilyl)amide (12 mL, 0.012 mol) and the reaction 
mixture was stirred for 1 hour at -70 ºC Then ethyl bromoacetate (1.33 mL, 0.012 mol) was 
added, and the reaction mixture was stirred at -70 ºC for 30 min., and then at room temperature 
for 18 hours. The solvent was removed in vacuo, and the residue was dissolved in AcOEt. The 
organic phase was washed with water, 5% aqueous solution of NaHCO3, and 5% HCl, dried over 
Na2SO4 and concentrated to give yellow oil, which was purified by column chromatography 
(petroleum ether/ethyl acetate 2/8) to give a pale yellow oil. Yield 65%. MS (EI): m/z [222, M+]. 
The 1H-NMR spectra was in accordance with that reported in literature.30 
Furo[2,3-h]cinnolin-3(2H)-one (11). A solution of α-hydroxy acid 6 (0.21 g, 0.0010 mol) in 
hydrazine hydrate (5 mL, 0.10 mol) was refluxed for 48 hours. After cooling the solid was 
filtered and washed with ethanol. The solid was then triturated with acetone, filtered to give a 
beige solid. Yield: 35%; mp 300 ºC dec. 1H-NMR (200 MHz, DMSO-d6): δ 14.00 (brs, 1H, NH), 
7.75 (s, 1H, Ar-H4), 7.68 (AB system, 2H, J = 9.0 Hz, Ar-H6 and Ar-H5), 7.62 (d, 1H, J = 1.8 
Hz, H8), 6.61 (d, 1H, J = 1.8 Hz, H9). MS (MALDI-TOF): [187, M
+ +1]. Anal. Calc. for 
C10H6N2O2: C, 64.52; H, 3.25; N, 15.05. Found: C, 64.34; H, 3.55; N, 14.91. 
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4-Amino-furo[2,3-h]cinnolin-3(2H)-one (12). From 6. A suspension of 6 (0.23 g, 0.0011 mol) 
in hydrazine hydrate (5 mL, 0.10 mol) was refluxed for 72 hours. After cooling the excess of 
hydrazine hydrate was evaporated and the residue was triturated with acetone. The solid formed 
was purified by flash chromatography eluting with dichloromethane/methanol 9.5/0.5 to give a 
brown solid. Yield: 40%. 
From 11. A suspension of 11 (0.20 g, 0.0011 mol) and hydrazine hydrate (5 mL, 0.10 mol) was 
refluxed for 24 hours. After cooling the excess of hydrazine hydrate was evaporated and the 
residue was triturated with acetone. The solid formed was purified by flash chromatography 
eluting with dichloromethane/methanol 9.5/0.5 to give a brown solid. Yield: 45%, mp 300 ºC 
dec. 1H-NMR (500 MHz, DMSO-d6): δ 7.58 (d, 1H, J = 9.3 Hz, Ar-H6), 7.07 (d, 1H, J = 9.3 Hz, 
Ar-H5), 7.21 (d, 1H, J = 1.9 Hz, Ar-H8), 6.69 (d, 1H, J = 1.9 Hz, Ar-H9). MS (MALDI-TOF): 
[202, M+ +1]. Anal. Calc. for C10H7N3O2: C, 59.70; H, 3.51; N, 20.89. Found: C, 59.75; H, 3.42; 
N,  21.09.  
4-Amino-1,2-dihydropyridazino[3,4-f]cinnolin-3-ol (13). A solution of 11 (0.22 g, 0.0011 
mol) in hydrazine hydrate (5 mL) was refluxed for 72 hours. After cooling the excess of 
hydrazine hydrate was evaporated. The residue was triturated with acetone, the solid filtrated and 
purified by flash chromatography eluting with dichloromethane/methanol 9.5/0.5 to give a green 
solid. Yield: 25%; mp 300 ºC dec. 1H-NMR (500 MHz, DMSO): δ 13.50 (brs, 1H, OH), 9.34 (d, 
1H, J = 5.6 Hz, Ar-H9), 8.47 (d, 1H, J = 5.6 Hz, Ar-H10), 8.06 (d, 1H, J = 9.0 Hz, Ar-H6), 7.64 
(brs, 2H, NH), 7.58 (d, 1H, J = 9.0 Hz, Ar-H5), 6.20 (s, 2H, NH2). MS (EI): (m/z): [216, M
+ +1], 
198, 183, 157. Anal. Calc. for C10H9N5O: C, 55.81; H, 4.22; N, 32.54. Found: C, 55.60; H, 4.02; 
N, 32.65.  
1,2-Dihydrofuro[2,3-h]cinnolin-3(4H)-one (14). A mixture of 3 (0.19 g, 0.0010 mol) (in 
hydrazine hydrate (5 mL, 0.10 mol) was refluxed for 15-30 minutes. After cooling the product 
was filtered, washed with water to give a beige solid. Yield: 55%; mp 300 ºC dec. 1H-NMR (200 
MHz, DMSO-d6): δ 7.94 (d, 1H, J = 8.8 Hz, H6); 7.20 (d, 1H, J = 8.8 Hz, H5); 7.18 (s, 2H, H8, 
H9); 5.33 (bs, 2H, NH); 5.59 (s, 2H, H4). MS (EI): (m/z): [188, M
+, 100%], 158, 131, 129, 117, 
105. Anal. Calc. for C10H8N2O4: C, 63.82; H, 4.28; N, 14.89. Found: C, 63.98; H, 4.03; N, 15.22. 
Biological materials, chemicals, and enzymes 
All compounds were dissolved in DMSO and the stock solutions were stored at -20 °C. The 
γ[32P]-ATP was purchased from PerkinElmer. The expression system for wild-type IN was a 
generous gift of Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH, Bethesda, 
MD. 
Integrase assays. Inhibition of IN catalytic activities, 3’-processing (3’-proc) and strand transfer 
(ST), were evaluated by oligonucleotide-based assays in in vitro assays employing purified 
enzyme as previously described.15 
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